利用小RNA早期检测肺癌
研究前瞻性招募1384名符合国家肺癌筛查试验人口学标准的个体,通过超深度小RNA测序开发出18个小RNA特征签名(miLung),在发现队列中诊断模型的中位ROC曲线下面积为0.86(95%CI:0.84-0.86),验证队列为0.83。数据提示基于小RNA的血液检测可能作为低剂量计算机断层扫描筛查的可行替代方案,用于吸烟相关肺癌的早期检测。
要点
- miLung签名在发现队列中位AUC为0.86(95%CI:0.84-0.86),验证队列为0.83。
- 诊断性能随分期增加而提高,发现队列I期AUC为0.73(95%CI:0.71-0.76),IV期为0.90(95%CI:0.89-0.90)。
- L1 stalk的肿瘤脱落血浆结合核糖体RNA片段是肺癌的主要预测因子,根治性手术后该片段减少。
核心结论
- 数据提示基于小RNA的血液检测可能作为低剂量计算机断层扫描筛查的可行替代方案,用于吸烟相关肺癌的早期检测。
研究设计与样本
- 使用943名个体的小RNA表达,通过100次随机数据拆分训练和评估逻辑回归分类器集成,发现18个小RNA特征共识签名(miLung)。
- 在独立队列(441名个体)中验证该签名,并进行血细胞分选和肿瘤组织测序以解析小RNA来源。
主要发现
- 发现队列中诊断模型的中位ROC曲线下面积为0.86(95%CI:0.84-0.86),验证队列的泛化性能为0.83。
- 发现队列中诊断性能随分期增加而提高,I期AUC为0.73(95%CI:0.71-0.76),IV期为0.90(95%CI:0.89-0.90);验证队列从0.76到0.86。
- L1 stalk的肿瘤脱落血浆结合核糖体RNA片段被确定为肺癌的主要预测因子,根治性手术后该片段减少。
- 干血斑收集和测序实验结果表明,小RNA分析可能通过家庭采样进行。
关键数值与推荐
- 发现队列中位AUC为0.86(95%CI:0.84-0.86),验证队列泛化性能为0.83。
- 发现队列I期AUC为0.73(95%CI:0.71-0.76),IV期为0.90(95%CI:0.89-0.90);验证队列从0.76到0.86。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lung cancer remains the deadliest cancer in the world, and lung cancer survival is heavily dependent on tumor stage at the time of detection. Low-dose computed tomography screening can reduce mortality; however, annual screening is limited by low adherence in the United States of America and still not broadly implemented in Europe. As a result, less than 10% of lung cancers are detected through existing programs. Thus, there is a great need for additional screening tests, such as a blood test, that could be deployed in the primary care setting. METHODS: We prospectively recruited 1384 individuals meeting the National Lung Screening Trial demographic eligibility criteria for lung cancer and collected stabilized whole blood to enable the pipetting-free collection of material, thus minimizing preanalytical noise. Ultra-deep small RNA sequencing (20 million reads per sample) was performed with the addition of a method to remove highly abundant erythroid RNAs, and thus open bandwidth for the detection of less abundant species originating from the plasma or the immune cellular compartment. We used 100 random data splits to train and evaluate an ensemble of logistic regression classifiers using small RNA expression of 943 individuals, discovered an 18-small RNA feature consensus signature (miLung), and validated this signature in an independent cohort (441 individuals). Blood cell sorting and tumor tissue sequencing were performed to deconvolve small RNAs into their source of origin. RESULTS: We generated diagnostic models and report a median receiver-operating characteristic area under the curve of 0.86 (95% confidence interval [CI]: 0.84-0.86) in the discovery cohort and generalized performance of 0.83 in the validation cohort. Diagnostic performance increased in a stage-dependent manner ranging from 0.73 (95% CI: 0.71-0.76) for stage I to 0.90 (95% CI: 0.89-0.90) for stage IV in the discovery cohort and from 0.76 to 0.86 in the validation cohort. We identified a tumor-shed, plasma-bound ribosomal RNA fragment of the L1 stalk as a dominant predictor of lung cancer. The fragment is decreased after surgery with curative intent. In additional experiments, results of dried blood spot collection and sequencing revealed that small RNA analysis could potentially be conducted through home sampling. CONCLUSIONS: These data suggest the potential of a small RNA-based blood test as a viable alternative to low-dose computed tomography screening for early detection of smoking-associated lung cancer.
引用
- Sikosek T, Horos R, Trudzinski F, et al. Early Detection of Lung Cancer Using Small RNAs. J Thorac Oncol. 2023. PMID: 37437883. doi:10.1016/j.jtho.2023.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。